Melanoma Dispatch
Follow
Find tag "genome"
2.1K views | +0 today
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Rescooped by Cancer Commons from Prostate Cancer Dispatch
Scoop.it!

Landmark Gift of $100 Million from the Marie-Josée and Henry R. Kravis Foundation Will Support Groundbreaking Approach to Precision Oncology at Memorial Sloan Kettering Cancer Center

Landmark Gift of $100 Million from the Marie-Josée and Henry R. Kravis Foundation Will Support Groundbreaking Approach to Precision Oncology at Memorial Sloan Kettering Cancer Center | Melanoma Dispatch | Scoop.it

"Memorial Sloan Kettering Cancer Center today launched an ambitious initiative to improve cancer care and research through genomic analysis. The new program will reshape clinical trials and speed the translation of novel molecular discoveries into routine clinical practice...


“ 'Progress in our understanding of the biology of cancer has completely shifted the way we think about and treat cancer,' says Craig Thompson, MD, MSK President and CEO. 'We’re moving away from the concept of treating cancer as many different types of the same disease and toward treating each person’s cancer as its own unique disease. Now, thanks to the inspiring generosity of the Marie-Josée and Henry R. Kravis Foundation, we will be able to expand and intensify this effort, ushering in what will truly be a new era of precision medicine.' ”


Editor's note: Learn more about personalized approaches to cancer treatment.

Cancer Commons's insight:

Yahoo!  |  May 20, 2014

more...
Cancer Commons's curator insight, May 20, 6:54 PM

Yahoo!  |  May 20, 2014

Cancer Commons's curator insight, May 20, 6:54 PM

Yahoo!  |  May 20, 2014

Rescooped by Cancer Commons from Prostate Cancer Dispatch
Scoop.it!

Cancer ‘Miracle’ Patients Studied Anew for Disease Clues

Cancer ‘Miracle’ Patients Studied Anew for Disease Clues | Melanoma Dispatch | Scoop.it

"The history of oncology is rife with reports of patients with advanced cancer who staged miraculous recoveries.


"Now scientists are starting to use sophisticated DNA sequencing technology to determine if these “exceptional responders” carry gene variations that can lead to new treatment approaches, better targeted therapies or even the re-emergence of experimental drugs once deemed failures.


"The mystery surrounding Jan Crisitello, a 70-year-old grandmother of four, is a case in point. Five years ago, 29 patients with advanced melanoma enrolled in a trial of a drug under development by Pfizer Inc. (PFE) Only one, Crisitello, came away with her cancer in remission. Now, she is being studied to see how her unique genome may have interacted with the drug to spur her recovery."


Editor's note: To learn more about personalized medicine, click here.

Cancer Commons's insight:

Bloomberg  |  Apr 10, 2014

more...
Cancer Commons's curator insight, April 11, 5:39 PM

Bloomberg  |  Apr 10, 2014

Cancer Commons's curator insight, April 11, 5:40 PM

Bloomberg  |  Apr 10, 2014

Rescooped by Cancer Commons from Lung Cancer Dispatch
Scoop.it!

Molecular Tumor Board Helps in Advanced Cancer Cases

Molecular Tumor Board Helps in Advanced Cancer Cases | Melanoma Dispatch | Scoop.it
With accelerating development of personalized cancer treatments matched to a patient's DNA sequencing, proponents say frontline physicians increasingly need help to maneuver through the complex genomic landscape to find the most effective, individualized therapy.


Editor's note: Learn more about personalized medicine and molecular (genetic) testing on our website.

Cancer Commons's insight:

Medical Xpress  |  May 5, 2014

more...
Cancer Commons's curator insight, May 5, 6:05 PM

Medical Xpress  |  May 5, 2014

Cancer Commons's curator insight, May 5, 6:06 PM

Medical Xpress  |  May 5, 2014

Scooped by Cancer Commons
Scoop.it!

Researchers Intensify Efforts to Solve Mysteries of Exceptional Responders

Researchers Intensify Efforts to Solve Mysteries of Exceptional Responders | Melanoma Dispatch | Scoop.it

"Exceptional responders — those patients with cancer who demonstrate sustained benefit from a therapy on which almost all others fail — have been observed in clinical trials for decades.


“ 'This is the basis of the urban legend story that everyone has heard — someone was given 2 months to live, but was given a drug and had a miraculous recovery,' William C. Hahn, MD, PhD, chief of the division of molecular cellular oncology at Dana-Farber Cancer Institute, told HemOnc Today.


"Because of recent strides in genomic sequencing, however, the phenomenon has evolved from a series of unexplained individual success stories into a collection of tremendously valuable case studies."

Cancer Commons's insight:

HemOnc Today  |  Jan 25, 2014

more...
Cancer Commons's curator insight, February 18, 1:57 PM

HemOnc Today  |  Jan 25, 2014

Cancer Commons's curator insight, February 18, 1:57 PM

HemOnc Today  |  Jan 25, 2014